Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer

CAMBRIDGE, Mass.& OSAKA, Japan--(BUSINESS WIRE) April 27, 2021-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news